Henry Schein stock holds above $90 as new dental partnership and investor interest support outlook
Published on 08/27/2026 at 17:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Henry Schein Inc. (ISIN US42548G1040) stock is trading above $90 in late August 2026, with a mix of new institutional interest and a fresh dental distribution partnership shaping the picture for investors as of August 27, 2026.
A recent market-data snapshot cited a last Henry Schein share price of $90.38 on August 26, 2026, up from a prior close of $76.85 USD, highlighting a notable gain in the stock over that period. A German-language performance analysis also showed that an investment held over the past three years would be worth $11,760.57 USD at that August 26, 2026 price, underscoring the longer-term appreciation of the shares.
That same analysis linked the recent price level of $90.38 USD to a three-year gain from an initial investment, giving investors a concrete sense of Henry Schein's ability to generate shareholder returns over a multi-year horizon, even before factoring in the latest operational developments.
Fresh institutional interest and valuation context
On August 27, 2026, a portfolio disclosure reported that shares of Henry Schein opened trading at $90.38 USD, reinforcing that the stock is holding close to the late-August highs implied by prior day data. The same disclosure noted new institutional buying of Henry Schein shares by an asset manager, highlighting continuing interest from professional investors at these price levels.
According to that August 27, 2026 report, Henry Schein currently carries an average analyst rating described as a moderate buy, with a consensus price target of $92.93 USD. With the stock opening at $90.38 USD on that date, the implied upside to the consensus target is $2.55 USD per share, or about 2.8 percent, suggesting that the shares are trading close to what analysts see as fair value while still offering a modest potential gain if the company delivers on expectations.
The same coverage underscored that multiple analysts have updated their views over recent months, feeding into that $92.93 USD consensus level. For investors, the small gap between the current price and the consensus target emphasizes that future share performance may depend on Henry Schein's ability to sustain revenue and earnings growth in its dental and medical supply businesses.
Operational backdrop and dental partnership
Operationally, Henry Schein continues to expand within the dental and oral-maxillofacial markets through its subsidiary BioHorizons. On August 27, 2026, a company news item detailed that Xtant Medical Holdings Inc. had entered an exclusive partnership with BioHorizons to distribute its allogeneic growth factor technology into dental and oral-maxillofacial applications. The report on that partnership framed the deal as a way to bring growth factor technology more broadly to dental clinicians via Henry Schein's established distribution channels.
The partnership, announced on August 27, 2026, reinforces Henry Schein's strategy of aligning with innovative therapeutic and biomaterial technologies that can enhance implant procedures and regenerative dentistry. By distributing Xtant Medical's growth factor products through BioHorizons, Henry Schein can leverage its scale in dental supply distribution while offering higher-value solutions that may support practice growth and patient outcomes.
For investors, this type of partnership matters because it can feed into segment revenue growth without requiring Henry Schein to develop the underlying technology in-house. Instead, the company can use its extensive sales network and customer base to drive adoption, which over time may show up in higher reported dental segment revenue and potentially improved margins if the products carry premium pricing.
Earnings backdrop and performance comparison
While the latest detailed quarterly financial figures for Henry Schein are not spelled out in the same-day results set, the data on the share price performance and analyst consensus still provide a useful frame. The three-year investment example highlighted in late August 2026 showed that an original position which would now be valued at $11,760.57 USD at $90.38 USD per share implies a substantial appreciation compared with the starting value three years prior. The three-year comparison thus provides a concrete benchmark for the company's share performance over a full business cycle.
Measured against the analyst consensus target of $92.93 USD as cited on August 27, 2026, the $90.38 USD opening price leaves Henry Schein trading within a narrow band of that valuation level. If future quarterly results show continued growth in dental and medical supply revenue, or if partnerships like the Xtant Medical-BioHorizons distribution agreement accelerate segment expansion, analysts could revisit their models, potentially revising forecasts and targets upward.
Conversely, if upcoming earnings reports reveal slower growth or margin pressure, the limited buffer between the current price and the consensus target could translate into more volatile share reactions around report dates. This dynamic makes the operational developments in Henry Schein's distribution and product portfolio, such as the new growth factor technology offering in dental markets, an important factor in assessing the stock.
Representative dental implant and biomaterials offering
A representative product area that illustrates Henry Schein's strategy is dental implants and associated biomaterials available through BioHorizons. Through this platform, Henry Schein distributes implant systems, regenerative solutions, and, with the August 27, 2026 announcement, allogeneic growth factor technology that supports bone and tissue healing in oral surgery.
For dental practitioners, such products can help improve clinical outcomes in implant placement and grafting procedures, potentially reducing healing times and increasing the predictability of restorative cases. From Henry Schein's perspective, offering advanced regenerative biomaterials alongside conventional dental supplies deepens relationships with practices and encourages cross-selling, which can support recurring revenue and enhance the value of the company's distribution network.
Henry Schein stock and late-August price context
Based on the most recent disclosed opening price of $90.38 USD for Henry Schein shares on August 27, 2026, the stock is trading only modestly below the $92.93 USD analyst consensus price target, highlighting a market view that already prices in a large share of expected near-term progress in the business.
The earlier closing price of $76.85 USD for Henry Schein highlighted in the three-year investment analysis shows that the move to $90.38 USD represents a gain of $13.53 USD per share over that interval, which equates to a 17.6 percent increase in the share price from that reference point. The fact that an investor's three-year holding would now be valued at $11,760.57 USD at the $90.38 USD price level underscores how steady appreciation and reinvestment can enhance portfolio value over time.
Read more
More on Henry Schein stock and corporate developments is available through the company's official investor information and the same-day coverage of its dental partnership and institutional activity.
Dental solutions within Henry Schein's portfolio
Within its broader portfolio, Henry Schein's role in bringing Xtant Medical's allogeneic growth factor technology to dental and oral-maxillofacial markets through BioHorizons reflects a focus on solutions that integrate biologics with implant dentistry. The August 27, 2026 partnership announcement described the technology as a way to deliver growth factors supporting tissue regeneration, with BioHorizons acting as the exclusive distributor for dental and oral-maxillofacial indications. The partnership coverage emphasized how the agreement expands Xtant's reach while deepening BioHorizons' regenerative offerings.
From an investor's perspective, such collaborations can be seen as adding layers of potential growth on top of Henry Schein's base business in supplies and equipment. Dental practices seeking to differentiate themselves increasingly adopt advanced biomaterials and growth factor products, and Henry Schein's distribution capacity can be a critical enabling factor. If adoption rates are strong, this can lead to measurable increases in segment revenue that may be reflected in forthcoming quarterly reports.
Stock valuation, analyst consensus, and performance
In late August 2026, the Henry Schein stock valuation narrative is anchored by three key figures: the $90.38 USD share price observed at the August 27, 2026 opening, the prior closing level of $76.85 USD used in a three-year investment performance example, and the $92.93 USD consensus price target reflecting aggregated analyst models. These datapoints together show a share price that has moved significantly higher over time yet remains within a narrow band relative to current analyst expectations.
The difference of $13.53 USD between the $76.85 USD reference close and the $90.38 USD price translates into a 17.6 percent uplift, a meaningful performance for a diversified healthcare distributor. Meanwhile, the $2.55 USD gap to the $92.93 USD consensus target indicates that, in the view captured by those models, Henry Schein's shares are not seen as dramatically overextended, but instead close to a level where incremental news or earnings surprises could tilt sentiment either way.
If future quarterly results confirm that partnerships such as the Xtant Medical-BioHorizons distribution agreement are translating into measurable growth, analysts may have reason to revisit forecasts and potentially adjust targets upward, supporting further gains. Should the data show slower growth, the tight proximity to the consensus target may lead to more cautious positioning among institutional investors, even as the company continues to benefit from long-term demand for dental and medical supplies.
Closing view on Henry Schein shares
As of August 27, 2026, Henry Schein stock trades at $90.38 USD in its latest opening quote, placing it just below the $92.93 USD consensus price target and reflecting both the solid three-year appreciation that lifted a hypothetical investment to $11,760.57 USD and the current market assessment of the company's growth prospects.
For investors, the combination of sustained share-price gains, active institutional buying, and strategic moves in dental biomaterials such as the growth factor technology partnership positions Henry Schein shares as closely aligned with analyst expectations, with future earnings and operational milestones likely to determine whether the stock extends its current trajectory.
Fact box
Company: Henry Schein Inc.
ISIN: US42548G1040
Ticker: HSIC
Exchange: Nasdaq
Price (as of August 27, 2026, opening quote): $90.38 USD
Market cap: not stated in same-day sources
Sector / Industry: Healthcare distribution and dental supplies
Index membership: Nasdaq Composite
